Главная/REGN

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze REGN in workspace
REGNNASDAQ/health care

Regeneron Pharmaceuticals, Inc.

$663.09Down-1,43 (-0,22%)
Research reviewed: 12 июл. 2026 г., 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Regeneron Pharmaceuticals, Inc. operates in Biotechnology within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Ouverture
661,63
Haut
665,60
Bas
655,11
Capitalisation
69,52 Md
Ratio C/B
16.20
Plus haut sur 52 semaines
--
Dividende
0.570%
Dividende trimestriel
--

3-month price context

График показывает недавний 3-месячный тренд, чтобы пользователи могли понять краткосрочную структуру перед открытием полного рабочего кабинета.

Investment thesis

Base case
New indications, age groups and geographies can extend a broad type-2 inflammation franchise. The base case remains conditional on retinal competition staying manageable.
Bull case
New indications, age groups and geographies can extend a broad type-2 inflammation franchise. Longer dosing intervals can support retinal share and physician adoption despite biosimilar entry. Bispecific antibodies, immunology assets and genetic medicines offer multiple routes to portfolio expansion.
Bear case
Biosimilars and rival long-duration therapies can erode EYLEA volume, pricing and share. Profit-sharing and dependence on collaborators shape the cash economics of major products. Late-stage oncology and immunology programs may fail to show sufficient efficacy or safety.
Thesis invalidation
Reassess the thesis if biosimilars and rival long-duration therapies can erode EYLEA volume, pricing and share.

Key catalysts

  • Dupixent expansion

    New indications, age groups and geographies can extend a broad type-2 inflammation franchise.

  • EYLEA HD conversion

    Longer dosing intervals can support retinal share and physician adoption despite biosimilar entry.

  • Internal pipeline

    Bispecific antibodies, immunology assets and genetic medicines offer multiple routes to portfolio expansion.

Principal risks

  • Retinal competition

    Biosimilars and rival long-duration therapies can erode EYLEA volume, pricing and share.

  • Partner economics

    Profit-sharing and dependence on collaborators shape the cash economics of major products.

  • Pipeline attrition

    Late-stage oncology and immunology programs may fail to show sufficient efficacy or safety.

Latest earnings research

Q1 2026

Regeneron's first-quarter 2026 update highlighted Dupixent's continued global expansion, execution across the EYLEA HD retinal franchise and investment in oncology, immunology and genetic-medicine programs.

Valuation interpretation

  • Dupixent durability and successful EYLEA HD conversion anchor value while retinal competition remains a material offset.
  • The internal pipeline deserves option value, but commercialization and partner economics require asset-by-asset risk adjustment.

Peer research

ABBVAMGNGILD

Recent news

Trefis · il y a 8 heures

Own Regeneron For Biotech Growth? Incyte Is Making Its Case.

Insider Monkey · il y a 11 heures

Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2

MT Newswires · il y a 5 jours

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

Insider Monkey · il y a 5 jours

Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?

Trefis · il y a 6 jours

Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside

24/7 Wall St. · il y a 6 jours

Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”

Data and research sources

Research updated: 12 июл. 2026 г., 00:00 UTC
3 verified sources
Regeneron Reports First Quarter 2026 Financial and Operating ResultsRegeneron Pharmaceuticals, Inc. · earningsVerified

Fetched: 12.07.2026, 0:00:00 UTC

Published: 30.04.2026, 00:00:00

Open original source
Regeneron Pharmaceuticals, Inc. Investor RelationsRegeneron Pharmaceuticals, Inc. · companyVerified

Fetched: 12.07.2026, 0:00:00 UTC

Open original source
Regeneron SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 12.07.2026, 0:00:00 UTC

Published: 30.04.2026, 00:00:00

Open original source

Continue in the research workspace

Keep REGN in context, run a multi-agent analysis, and monitor thesis changes.

Analyze REGN free

Изучить всю систему анализа

У каждого этапа своя задача и проверяемый результат.

Методология исследованияЧитать обзоры рынкаИзучить акции

Continue researching this stock

Market Analyst

Reads price structure, trend strength, and market posture before thesis formation.

Fundamentals Analyst

Owns business quality, earnings structure, and financial health.

News Analyst

Tracks what just happened and whether it actually changes the thesis.

Risk Manager

Sets the final risk classification and action boundaries after the risk debate.